Literature DB >> 12963807

Blocking the docking of HIV-1.

Aine McKnight1, Robin A Weiss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12963807      PMCID： PMC196843          DOI： 10.1073/pnas.2035071100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  17 in total

1.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.

Authors:  Peter D Kwong; Michael L Doyle; David J Casper; Claudia Cicala; Stephanie A Leavitt; Shahzad Majeed; Tavis D Steenbeke; Miro Venturi; Irwin Chaiken; Michael Fung; Hermann Katinger; Paul W I H Parren; James Robinson; Donald Van Ryk; Liping Wang; Dennis R Burton; Ernesto Freire; Richard Wyatt; Joseph Sodroski; Wayne A Hendrickson; James Arthos
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

Review 2.  HIV vaccines 1983-2003.

Authors:  Andrew J McMichael; Tomas Hanke
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

3.  A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.

Authors:  Pin-Fang Lin; Wade Blair; Tao Wang; Timothy Spicer; Qi Guo; Nannan Zhou; Yi-Fei Gong; H-G Heidi Wang; Ronald Rose; Gregory Yamanaka; Brett Robinson; Chang-Ben Li; Robert Fridell; Carol Deminie; Gwendeline Demers; Zheng Yang; Lisa Zadjura; Nicholas Meanwell; Richard Colonno
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-20       Impact factor: 11.205

4.  Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes.

Authors:  Loïc Martin; François Stricher; Dorothée Missé; Francesca Sironi; Martine Pugnière; Philippe Barthe; Rafael Prado-Gotor; Isabelle Freulon; Xavier Magne; Christian Roumestand; André Ménez; Paolo Lusso; Francisco Veas; Claudio Vita
Journal:  Nat Biotechnol       Date:  2002-12-16       Impact factor: 54.908

5.  Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults.

Authors:  J M Jacobson; I Lowy; C V Fletcher; T J O'Neill; D N Tran; T J Ketas; A Trkola; M E Klotman; P J Maddon; W C Olson; R J Israel
Journal:  J Infect Dis       Date:  2000-06-30       Impact factor: 5.226

6.  Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication.

Authors:  P Kolchinsky; T Mirzabekov; M Farzan; E Kiprilov; M Cayabyab; L J Mooney; H Choe; J Sodroski
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

7.  Twenty years of therapy for HIV-1 infection.

Authors:  Roger J Pomerantz; David L Horn
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

8.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

9.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

10.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

Authors:  Jacob P Lalezari; Keith Henry; Mary O'Hearn; Julio S G Montaner; Peter J Piliero; Benôit Trottier; Sharon Walmsley; Calvin Cohen; Daniel R Kuritzkes; Joseph J Eron; Jain Chung; Ralph DeMasi; Lucille Donatacci; Claude Drobnes; John Delehanty; Miklos Salgo
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245
View more
  1 in total

Review 1.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.